PRIMA BIOMED TO COMMENCE DISCUSSIONS WITH POTENTIAL...

PRIMA BIOMED TO COMMENCE DISCUSSIONS WITH POTENTIAL NORTH
AMERICAN INVESTMENT PARTNERS
Australian health care company Prima BioMed (Prima) (ASX:

Mr Rogers is "commencing dicussions" so we may not have any news in this area this week. IMO GN

PRR) is pleased to
announce that it will commence discussions with potential major North American
institutional investment funds later this month for the development of its core product,
the CVac™ ovarian cancer therapy vaccine.
On the back of the continued strong progress towards the commercialisation of
CVac™, the Company has received significant interest from a number of major
institutional investment groups, and Prima’s executive director, Mr Martin Rogers, will
begin discussions in North America with a number of hedge funds and other biotechfocused
investment funds on new investment and partnering opportunities for the
comercialisation of CVac™.